Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers
about
Early diagnosis of pancreatic cancer: challenges and new developmentsGlycoproteins and glycoproteomics in pancreatic cancerSegment and fit thresholding: a new method for image analysis applied to microarray and immunofluorescence data.The Marker State Space (MSS) method for classifying clinical samples.Detection of distinct glycosylation patterns on human γ-glutamyl transpeptidase 1 using antibody-lectin sandwich array (ALSA) technology.Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution.Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens.Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9.CA 19-9 and pancreatic cancer.iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance.Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?Specific glycoforms of MUC5AC and endorepellin accurately distinguish mucinous from nonmucinous pancreatic cysts.Using antibody arrays to measure protein abundance and glycosylation: considerations for optimal performance.Prediction of glycan motifs using quantitative analysis of multi-lectin binding: Motifs on MUC1 produced by cultured pancreatic cancer cells.Characterizing Protein Glycosylation through On-Chip Glycan Modification and ProbingDiscovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arraysHigh-Throughput Analysis of Plasma Hybrid Markers for Early Detection of Cancers.Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers.Mucins in pancreatic cancer and its microenvironment.Blood-based tests for colorectal cancer screening: do they threaten the survival of the FIT test?Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy.Upregulation of glycans containing 3' fucose in a subset of pancreatic cancers uncovered using fusion-tagged lectins.Purity of islet preparations and 5-year metabolic outcome of allogenic islet transplantation.Ramifications of Secreted Mucin MUC5AC in Malignant Journey: A Holistic View.Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors.Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma.The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer
P2860
Q27014027-967419C3-BF01-46E9-B47C-BFDE512E4C4EQ28071108-77EA2054-C97F-4553-BB52-CE0C8C819220Q30991545-25F9D2E6-9ADA-4FB7-A1DA-016133E58CB2Q34764369-B379AF2A-A005-49A5-8339-482826D5BBF1Q34979254-F389B4AB-F1E1-4E5E-982D-855C1A25DB68Q35046670-4547B587-78BC-4059-992D-58C60D80FF2CQ35583350-30FBBD68-9A09-4F84-B01F-693642DE0042Q35797487-B4E5CCEE-28E0-402B-A47C-BE684A782227Q36687536-381E4209-BE2A-43ED-A21A-C750ADCDD716Q36786361-51BAA5EA-3FBD-417B-A20E-E55A8467A7A1Q36857512-1A0DF7BE-CBDA-4980-B21A-EF7D15962CD3Q37151056-A1EE7EA9-F43A-48AF-ACF8-CBC65517041EQ37214656-ECE724F7-6DCF-4573-A55C-D96CD8D9EA16Q37576547-80439F45-64B7-4C7F-9170-4C0B046B5AF6Q37593820-F24FB22D-0864-4132-873E-1CA189B21D5CQ37623120-208BB397-8C07-4785-BB1F-CE2F0D29D0D9Q37625192-B226E7FD-C27B-4FA7-BBAB-CD399BBA6B0AQ37636426-19047D06-728B-4A4E-8AA4-37767DF6FD0AQ37728199-3951E347-9450-40DD-8D83-A07F6A2DD8B5Q38121746-D2ECA95B-3853-4783-8BC6-B0ADCCD6728DQ38355111-2BB3ED08-CE61-4A09-AE91-3D968CABAC8CQ39410445-F278F903-B7E3-460C-B11D-7F673E047FCCQ40980684-0996DB51-AA40-497B-BC47-568446A483FCQ49896536-99177265-B12E-437B-8A24-1D1CDDDFA695Q50133047-020DCE7D-D990-4EC6-80FA-D53D77B28013Q52595056-12693724-F9E2-49F7-87C9-1A8A9EA95061Q53140408-1C01B2B5-AA17-4438-B3B8-61AC0782A9A1Q55424250-52C12DB5-9AB1-41AC-9FE3-A65FA3EB795BQ58780532-9D319A2C-BC31-4E97-A063-B1D836B0FE7E
P2860
Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Enhanced discrimination of mal ...... n on specific protein carriers
@ast
Enhanced discrimination of mal ...... n on specific protein carriers
@en
Enhanced discrimination of mal ...... n on specific protein carriers
@nl
type
label
Enhanced discrimination of mal ...... n on specific protein carriers
@ast
Enhanced discrimination of mal ...... n on specific protein carriers
@en
Enhanced discrimination of mal ...... n on specific protein carriers
@nl
prefLabel
Enhanced discrimination of mal ...... n on specific protein carriers
@ast
Enhanced discrimination of mal ...... n on specific protein carriers
@en
Enhanced discrimination of mal ...... n on specific protein carriers
@nl
P2093
P2860
P1433
P1476
Enhanced discrimination of mal ...... n on specific protein carriers
@en
P2093
A James Moser
Brian B Haab
Brian Fallon
Dean E Brenner
Diane M Simeone
Herbert Zeh
Karen Kaul
Katie Partyka
Kevin A Maupin
P2860
P304
P356
10.1371/JOURNAL.PONE.0029180
P407
P577
2011-12-29T00:00:00Z